Predicting the therapeutic response in patients with chronic hepatitis C: The role of viral kinetic studies

Journal of Antimicrobial Chemotherapy

Volumn 53, Issue 1, 2004, Pages 15-18

  Ferenci, Peter ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

HCV; Outcome prediction; Therapy

Indexed keywords

INTERFERON REGULATORY FACTOR 3; INTERFERON REGULATORY FACTOR 7; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROTEIN KINASE; RIBAVIRIN; VIRUS ENVELOPE PROTEIN; VIRUS RNA;

ACCURACY; ANTIVIRAL ACTIVITY; ARTICLE; CHRONIC DISEASE; COST CONTROL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG RESPONSE; GENOTYPE; HEALTH CARE COST; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; KINETICS; OUTCOMES RESEARCH; PREDICTION; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; VIRUS LOAD; VIRUS REPLICATION; VIRUS STRAIN;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; KINETICS; POLYETHYLENE GLYCOLS; PROGNOSIS; RIBAVIRIN; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0347917223     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh015     Document Type: Article

References (38)

1. Choo, Q. L., Kuo, G., Weiner, A. J. et al. (1989). Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244, 359-62.
2. McHutchison, J. G., Gordon, S. C., Schiff, E. R. et al. (1998). Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. New England Journal of Medicine 339, 1485-92.
3. Poynard, T., Marcellin, P., Lee, S. S. et al. (1998). Randomised trial of interferon alfa2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352, 1426-32.
4. Fried, M. W., Shiffman, M. L., Reddy, K. R. et al. (2002). Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine 347, 975-82.
5. Hadziyannis, S. J., Cheinquer, H., T. M., al. e. (2002). Peginterferon alfa-2a (40KD) (PEGASYS) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and RBV dose. Annals of Internal Medicine 193, in press.
6. Manns, M. P., McHutchison, J. G., Gordon, S. C. et al. (2001). Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358, 958-65.
7. National Institutes of Health. (2003). Consensus Development Conference Statement: Management of Hepatitis C: 2002 - June 10-12, 2002. Hepatology 36, Suppl. 1, S3-20.
8. Perelson, A. S., Neumann, A. U., Markowitz, M. et al. (1996). HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271, 1582-6.
9. Gale, M. J. & Katze, M. G. (1998). Molecular mechanisms of interferon resistance mediated by viral-directed inhibition of PKR, the interferon-induced protein kinase. Pharmacology and Therapeutics 78, 29-46.
10. Taylor, D. R., Shi, S. T., Romano, P. R. et al. (1999). Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 285, 107-10.
11. Paterson, M., Laxton, C. D., Thomas, H. C. et al. (1999). Hepatitis C virus NS5A protein inhibits interferon antiviral activity, but the effects do not correlate with clinical response. Gastroenterology 117, 1187-97.
12. Heim, M. H., Moradpour, D. & Blum, H. E. (1999). Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway. Journal of Virology 73, 8469-75.
13. Sen, G. C. (2001). Viruses and interferons. Annual Review of Microbiology 55, 255-81.
14. Grandvaux, N., Servant, M. J. & tenOever, B. et al. (2002). Transcriptional profiling of interferon regulatory factor 3 target genes: direct involvement in the regulation of interferon-stimulated genes. Journal of Virology 76, 5532-9.
15. Lin, R., Genin, P., Mamane, Y. et al. (2000). Selective DNA binding and association with the CREB binding protein coactivator contribute to differential activation of alpha/beta interferon genes by interferon regulatory factors 3 and 7. Molecular and Cellular Biology 20, 6342-53.
16. Foy, E., Wang, C., Sumpter, R. J. et al. (2003). Regulation of interferon regulatory factor-3 by the Hepatitis C virus serine protease. Science 300, 1145-8.
17. Hofer, H., Watkins-Riedel, T., Janata, O. et al. (2003). Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology 37, 60-4.
18. Gerlach, J. T., Diepolder, H. M., Zachoval, R. et al. (2003). Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 125, 80-8.
19. Holzmann, H., Aberle, J. H., Steindl-Munda, P. et al. (2003). Virus-specific CD4+ T cell responses in hepatitis C virus-infected patients with different genotypes. Poster presented at 54th Annual Meeting of the American Association for the Study of Liver Disease; October 24-28, 2003; Boston, MA, USA.
20. Nguyen, T. T., Sedghi-Vaziri, A., Wilkes, L. B. et al. (1996). Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection. Journal of Viral Hepatitis 3, 75-8.
21. Zeuzem, S., Franke, A., Lee, J. H. et al. (1996). Phylogenetic analysis of hepatitis C virus isolates and their correlation to viremia, liver function tests, and histology. Hepatology 24, 1003-9.
22. Jessner, W., Gschwantler, M., Steindl-Munda, P. et al. (2001). Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study. Lancet 358, 1241-2.
23. Lam, N. P., Neumann, A. U., Gretch, D. R. et al. (1997). Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 26, 226-31.
24. Jessner, W., Gschwantler, M., Formann, E. et al. (2003). Early viral kinetics in chronic hepatitis C virus genotype 4 infection. Paper presented at Digestive Diseases Week; May 17-22, 2003; Orlando, FL, USA.
25. Ferenci, P. (2003). Weight based dosing of pegylated interferon-alfa in chronic hepatitis C - just a marketing 'gag'? Digestive and Liver Disease 35, in press.
26. Ferenci, P., Gschwantler, M., Laferl, H. et al. (2003). Prospective evaluation of the 24 hour interferon-induced decline in hepatitis C virus genotype 1 load to predict response to peginterferon-alfa2a/ribavirin combination therapy. Abstract. Gastroenterology 124, Suppl. 1, A767.
27. Zeuzem, S., Herrmann, E., Lee, J. H. et al. (2001). Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology 120, 1438-47.
28. Herrmann, E., Lee, J. H., Marinos, G. et al. (2003). Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 37, 1351-8.
29. Neumann, A. U., Lam, N. P., Dahari, H. et al. (2000). Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. Journal of Infectious Diseases 182, 28-35.
30. Layden-Almer, J. E., Ribeiro, R. M., Wiley, T. et al. (2003). Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology 37, 1343-50.
31. Bekkering, F. C., Stalgis, C., McHutchison, J. G. et al. (2001). Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model. Hepatology 33, 419-23.
32. Glue, P., Fang, J. W., Rouzier-Panis, R. et al. (2000). Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clinical Pharmacology and Therapeutics 68, 556-67.
33. Buti, M., Sanchez-Avila, F., Lurie, Y. et al. (2002). Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. Hepatology 35, 930-6.
34. Formann, E., Jessner, W., Bennett, L. et al. (2003). Twice weekly administration of peginterferon-alfa-2b improves viral kinetics in patients with chronic hepatitis C genotype 1. Journal of Viral Hepatitis 10, 271-6.
35. Jessner, W., Stauber, R., Hackl, F. et al. (2003). Early viral kinetics on treatment with pegylated interferon-alpha-2a in chronic hepatitis C virus genotype 1 infection. Journal of Viral Hepatitis 10, 37-42.
36. Ferenci, P., Brunner, H., Nachbaur, K. et al. (2001). Combination of interferon induction therapy and ribavirin in chronic hepatitis C. Hepatology 34,1006-11.
37. Ferenci, P., Fried, M. A., Chaneac, M. (2003). A dynamic model to predict sustained virological response to combination peginterferon alfa-2a (40KD) (PEGASYS®) and ribavirin (COPEGUS®) therapy in patients with chronic hepatitis C. Poster presented at the 54th Annual Meeting of the American Association for the Study of Liver Disease; October 24-28, 2003; Boston, MA, USA.
38. McHutchison, J. G., Manns, M., Patel, K. et al. (2002). Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 123, 1061-9.